Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 11/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764436 | 0.90 | AGTR1 (0.45) | AGTR1LTB4R2ABCB11GP6MAPT | |
| SCHEMBL5820459 | 0.84 | MAPT (0.33) | MAPT | |
| SCHEMBL4792289 | 0.81 | AGTR1 (0.48) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL5529478 | 0.78 | AGTR1 (0.55) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL5525948 | 0.77 | AGTR1 (0.48) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL4773251 | 0.76 | EDNRA (0.58) | AGTR1 | |
| SCHEMBL4773395 | 0.75 | AGTR1 (0.47) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL4773514 | 0.74 | EDNRA (0.58) | AGTR1 | |
| SCHEMBL4774042 | 0.74 | ALOX5AP (0.36) | MAPT | |
| SCHEMBL4764477 | 0.73 | AGTR1 (0.45) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2002837-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1094816-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1237888-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| US-6852745-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-08 | — | — | US | disclosed |
| US-6835741-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-28 | — | — | US | disclosed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | disclosed |
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | disclosed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | AGTR1 4/4885LTB4R2 624/4885ABCB11 1057/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | AGTR1 4/4885LTB4R2 624/4885ABCB11 1057/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | AGTR1 4/4885LTB4R2 624/4885ABCB11 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.